SOPHiA GENETICS SA (SOPH) Stock Analysis

Price updated 4 days ago · SEC data refreshed 3 months ago · Not investment advice

SOPHiA GENETICS SA

SOPH Technology Data Processing & Hosting📄 SEC filings ↗
Valuation N/A
▾ What's in the 31/100 risk score? (higher = riskier)
Fundamental health (43%) 20/100 → +8.6
leverage 20/100
Smart money (short interest + insider buying) (31%) 45/100 → +14.1
Macro backdrop (VIX, curve, credit, fear/greed + week-over-week momentum) (26%) 33/100 → +8.5
Total31/100

Contributions (weight × component score) sum to the total. This near-term score now includes fundamental health (leverage, FCF trend). See the Financial Health section for the full balance-sheet read.

💵 Price $7.87 · 4 days ago 📄 Financials SEC EDGAR · refreshed 3 months ago

How to read SOPH (pre-profit growth)

This company is reinvesting instead of generating profit, so a standard DCF cannot price it. The useful question is whether the growth the market is paying for is achievable — and whether the company can fund itself until then.

Where to start — the sections that matter most for this stock
  1. 1 Reverse-DCF — the growth the price demands ↓
    It shows exactly how fast the business must grow to justify today's price. Compare that to what comparable companies have actually achieved.
  2. 2 Cash runway ↓
    Can it reach profitability before it has to raise money and dilute shareholders?
  3. 3 Interactive calculator ↓
    Set your own growth + margin assumptions and see what the business would be worth if you are right.
Or — what are you trying to decide?
A note on process: fear-driven decisions — including fear of missing out — tend to be the expensive ones. A stock up 10% a day for three days is excitement, not evidence. Whichever reader you are, the data below is there to be checked before anything is decided.
🚀
"It's surging — should I chase it?"
The momentum / FOMO trade. Before you chase, see whether the people who know it best are quietly selling into the rally.
🏷️
"Is it a cheap bargain?"
The deep-value trade. How far below assets and our value it trades — and whether it's cheap for a reason.
ⓘ Using the right valuation lens for this business type

Standard DCF doesn't fit SOPH well — but that's expected for this kind of business. The Rule of 40 (Pre-Profit Growth) Lens below uses the metrics actually used by analysts who value data processing & hosting. Reverse DCF + Football Field also work as cross-checks.

ⓘ Why does SOPH trade at $7.87?

SOPHiA GENETICS SA has 68.5 million shares outstanding. At $7.87 per share, the market values all outstanding SOPH equity at $539 million. That's market capitalization, not enterprise value — enterprise value also accounts for debt and cash (SOPH carries little or no debt, so the two are close here). The share price by itself tells you almost nothing — a company can pick any share price by splitting or issuing more shares. What matters is the total value (Market Cap?Market Cap — The total dollar value the market is assigning to the entire company.
Why it matters: This is the number that actually matters when comparing companies. Two companies with the same business but different share counts have the same market cap.
Reference: Mega cap >$200B · Large $10–200B · Mid $2–10B · Small $300M–2B · Micro <$300M
Full explanation →
) compared to what the business actually produces. This page values SOPH in Per Share?Per Share — A company-level figure divided by total shares — what one share represents.
Why it matters: Per-share metrics are the only way to fairly compare two companies with different share counts.
Full explanation →
economics — what each share represents of the underlying business. Play with the share-price calculator on the homepage →

Loading insider & short-seller data…
Checking filings for failure warnings…

How does SOPH stack up against its closest peers?

We take the 8 same-industry companies most similar to SOPH (similar size) and check what investors are paying for each dollar of their revenue (or profits). If SOPH is much more expensive on the same yardstick, that's a red flag — unless you have a specific reason it deserves a premium. For a leveraged business, EV/EBIT and FCF yield (both in the table) are usually more reliable than EV/Sales, because revenue multiples ignore differences in margins and debt.

▾ What's "EV / Sales" in plain English?

EV (Enterprise Value) = market cap + total debt − cash. It's "what you'd pay to buy the entire company outright" — you pay the market cap to shareholders and take over their debt, but you keep their cash. EV is fairer than market cap alone because it includes the debt the new owner inherits.

EV / Sales = EV ÷ annual revenue. So "2.5×" means investors pay $2.50 of enterprise value per $1 of yearly sales. Higher = market is paying more per dollar of sales (usually because they expect future growth or fat margins).

p25 / median / p75 are the 25th, 50th (middle), and 75th percentile of the peers' multiples. Half the peers fall between p25 and p75. The median (p50) is the typical peer — that's the benchmark we compare to.

What peers trade at (p25 / median / p75)
EV / Sales?EV / Sales — For every $1 of yearly revenue, this is how many dollars investors pay to own the whole business (including debt).
Why it matters: Works for pre-profit growth companies where P/E and FCF don't apply. The most apples-to-apples cross-company multiple because it ignores accounting choices.
Reference: 1–3x for mature companies · 4–10x for software/SaaS · 10–20x for hypergrowth · >20x is rare and demanding
Full explanation →
0.7x / 1.1x / 2.0x
EV / Gross Profit?EV / Gross Profit — Enterprise value divided by gross profit — the multiple paid for what each dollar of sales contributes after direct costs.
Why it matters: More refined than EV/Sales for high-margin businesses (software, marketplaces) where gross margin is the real economic engine.
Reference: 8–15x for SaaS · 15–25x for hypergrowth software · >30x demanding
Full explanation →
1.8x / 3.2x / 25.1x
EV / EBIT?EV / EBITDA — Enterprise value divided by earnings before interest, tax, depreciation, and amortization.
Why it matters: A classic "what would a private buyer pay" multiple — used in M&A. Strips out tax and capital-structure noise.
Reference: 8–12x for mature businesses · 15–25x for growth · Below 5x often signals distress
Full explanation →
8.7x / 9.0x / 13.8x

Bold middle number = median peer. Half the peers trade above it, half below. Computed over 8 same-industry peers; implausible multiples excluded.

Peer-implied value check
Peer-implied price isn't available for SOPH right now. The multiples table above still works as context.

⚠️ Important caveat: peer multiples only work if the peers are genuinely comparable. Always check the peer list below — if the auto-picker grabbed micro-caps or unrelated businesses, the comparison is noise. A medical-device giant priced against tiny biotech startups won't produce a useful signal.

▾ View peer list (8)
Ticker Company Industry Mcap EV/Sales EV/GPEV/EBIT FCF Yield
SSTK Shutterstock, Inc. Data Processing & Hosting $547M 0.7x 8.8x 11.6%
YEXT Yext, Inc. Data Processing & Hosting $516M 1.4x 1.8x13.8x 17.9%
NRDS NERDWALLET, INC. Data Processing & Hosting $566M 0.7x 8.7x 15.6%
CARS Cars.com Inc. Data Processing & Hosting $575M 1.4x 17.1x 17.5%
TASK TaskUs, Inc. Data Processing & Hosting $589M 0.7x 5.9x 9.2%
OOMA OOMA INC Data Processing & Hosting $485M 2.0x 3.2x126.1x 1.4%
GRVY GRAVITY Co., Ltd. Data Processing & Hosting $447M 10.5x 25.1x157.2x 2.2%
IBEX IBEX Ltd Data Processing & Hosting $424M 0.8x 9.1x 4.4%

Quality & solvency checks

Cheap stocks can be cheap for a reason. These screens warn when a low valuation comes paired with structural fragility.

Altman Z-Score?Altman Z-Score — A bankruptcy-risk score combining 5 financial ratios into one number. Predictive of bankruptcy within 2 years.
Why it matters: Cheap-looking stocks (low P/E or P/B) often have low Z-scores because the market knows the company is dying. Z-score warns you before you fall into a value trap.
Reference: > 3.0 = safe zone · 1.81–3.0 = grey zone · < 1.81 = distress zone
Full explanation →
Not available for this filer

The Z-score needs working capital, retained earnings, EBIT, sales and total assets from the latest balance sheet, and at least one of those isn't reported in machine-readable form here — common for foreign private issuers. We leave it blank rather than compute a distress verdict from an estimated input. It doesn't affect the reported figures in the financial tables below.

Piotroski F-Score?Piotroski F-Score — A 9-point quality checklist scoring profitability, leverage, and operating efficiency.
Why it matters: High score = fundamentals improving. Low score = deteriorating. Especially powerful for filtering cheap stocks: cheap + high F-score historically outperforms; cheap + low F-score is often a value trap.
Reference: 7–9 = strong · 4–6 = mediocre · 0–3 = weak
Full explanation →
Not available for this filer

The F-score compares two consecutive years of income, cash-flow and balance-sheet data. We have 5 years of income data for this filer, but no machine-readable cash-flow statement — so several of the nine checks have no input at all. We show nothing rather than score a partial year against itself. The reported figures in the financial tables below are unaffected.

Price$7.87
Model IVNot applicable — DCF couldn't price this stock. The other valuation lenses on this page (reverse-DCF, peers, sector lens — whichever apply to this filer) carry the read instead.

A standard discounted cash flow?DCF — Discounted Cash Flow — sums up all future cash a business will produce, adjusted for the fact that future dollars are worth less than dollars today.
Why it matters: It is the most fundamentally honest valuation method when applicable — but only works for companies with predictable, positive cash flow.
Reference: Best for: mature, profitable businesses. Fails for: pre-profit growth, banks, REITs.
Full explanation →
valuation is not meaningful for SOPHiA GENETICS SA because the company has negative net income and negative free cash flow?Free Cash Flow (FCF) — Operating cash flow minus capital spending: cash left after a company covers operating costs, taxes and interest and reinvests in the business — but BEFORE repaying debt principal or paying dividends. The cash actually available to investors.
Why it matters: A company can show big profits on paper while burning through cash. FCF is what actually fills the bank account.
Reference: Healthy mature businesses convert 8–15% of revenue into FCF · Growth companies often negative
Full explanation →
, indicating it is not yet profitable. Investors are likely betting on the company's future growth potential in the data processing and hosting industry, particularly its ability to scale its AI-driven analytics platform. The primary quantifiable risk is the continued negative net income, which suggests ongoing cash burn without a clear path to profitability in the short term.

⚠️ FCF negative: revenue/margin growth model projects future cash flows from revenue trajectory.

As of 3 months ago

Anatomy of a share

What you're buying per share. Bars are at the same scale so you can see the relative size of revenue, costs, cash flow, and debt — not just read them in a table.

SOPH SOPHiA GENETICS SA stock anatomy showing per-share revenue, operating expenses, free cash flow, and debt
What's free cash flow / what do these mean?

Revenue per share — how much the business earns from customers, divided by the number of shares outstanding. Top of the income statement.

Earnings per share — profit left after operating costs, interest, and taxes, per share. Two versions appear on this page and are not interchangeable: GAAP diluted EPS uses the company's weighted-average diluted share count during the reporting period (this is the "earnings" in "price-to-earnings"); net income per current share divides annual net income by today's share count. They differ whenever the share count has changed.

Owner-earnings free cash flow per share — the cash the business produces for shareholders. Savng's owner-earnings FCF subtracts capital expenditures and stock-based compensation from operating cash flow (SBC is a real dilution cost even though it's non-cash). This is deliberately more conservative than "standard" FCF, which subtracts only capital expenditures — so our figure is lower than the headline FCF you'll see elsewhere. FCF funds dividends, buybacks, debt repayment, and acquisitions; a company can report positive earnings yet negative FCF.

Debt per share — total interest-bearing borrowings divided by shares. High debt-per-share next to thin FCF-per-share is a fragility signal.

What you actually need to decide

Every stock price is a disagreement. Here's the single thing that must go right for the bulls, the single thing that breaks the thesis, and the concrete signposts to watch so you can update your view as real results arrive.

🐂 The Bull Case
Operating cash flow must turn positive and demonstrate a clear path to sustained profitability, driven by increased platform adoption and recurring revenue streams.
🐻 The Bear Case
Continued negative net income, as seen in the latest period, implies ongoing cash burn and a need for further capital raises, potentially diluting existing shareholders.
📌 Signposts to watch — update your view as these print
  • Acceleration in subscription revenue growth
  • Improvement in gross margins
  • Reduction in operating expenses relative to revenue

The trend, in plain numbers (FY2024 → FY2025, latest reported)

Straight from the financial statements — no model, no opinion. For a small or unprofitable company, the direction of these numbers usually tells you more than any single valuation.

⚠ Worsening
  • Still unprofitable at -$79.0M — loss widening.

Nothing was clearly improving year-over-year.

Management & Leadership

Jurgi Camblong is the co-founder and CEO of SOPHiA GENETICS SA, a role he has held since the company's inception. He is a key figure in driving the company's vision for data-driven medicine. Lara Smith is the Chief Financial Officer.

Jurgi Camblong
Chief Executive Officer
Lara Smith
Chief Financial Officer

What They Make

SOPHiA GENETICS SA provides an AI-driven analytics platform for healthcare institutions, enabling them to analyze complex genomic and radiomic data. Its customers are primarily hospitals, laboratories, and research institutions seeking to improve diagnostics and personalized medicine.

End Markets

Clinical DiagnosticsBiopharmaceutical ResearchPrecision Medicine

Revenue Drivers

Platform Subscriptions
Data Analysis Services
Strategic Partnerships
Market Cap: 539.0MBeta: 1.66

Why Is It Priced Like This?

Why Customers Pay

Enhanced diagnostic accuracy through AI
Streamlined data analysis workflows
Access to a global data network for insights
No discounted-cash-flow value for this filer No machine-readable cash-flow statement in this filer's EDGAR submissions — common for foreign private issuers (20-F/6-K). That makes a discounted-cash-flow valuation impossible: there is no free cash flow to discount. It does not affect the income-statement or balance-sheet figures below.

What we use instead: earnings (P/E, EV/EBIT), book value (P/B) — computed from the figures this company does report, shown in the sections below. Those numbers are unaffected by the missing cash-flow data.

The market is likely pricing SOPH based on its future growth potential in the rapidly evolving field of AI-driven healthcare analytics, rather than current cash flows, as indicated by its negative net income. The market may be assigning value to the potential for its AI platform to become a standard in genomic and radiomic data analysis, which is not in the model. Investors are focused on revenue growth and the company's ability to achieve scale and eventually profitability in a high-growth sector.

Business Model & Valuation

How They Make Money

Subscription fees for platform access
Usage-based fees for data analysis
Partnerships and collaborations for data insights

The company funds its operations and growth primarily through equity raises, given its negative free cash flow?Free Cash Flow (FCF) — Operating cash flow minus capital spending: cash left after a company covers operating costs, taxes and interest and reinvests in the business — but BEFORE repaying debt principal or paying dividends. The cash actually available to investors.
Why it matters: A company can show big profits on paper while burning through cash. FCF is what actually fills the bank account.
Reference: Healthy mature businesses convert 8–15% of revenue into FCF · Growth companies often negative
Full explanation →
and lack of dividend payments or buybacks.

Growth / Revenue DCF

No cash flow statement data available - using revenue/margin growth model as fallback.

Show advanced inputs
Revenue Growth15.0%

What this model does NOT do: this is a consolidated owner-earnings FCF model. Standalone segment assumptions: none. It does not project product, services and recurring/cloud lines independently; their combined effect is embedded in the historical revenue and cash-flow trend the model extrapolates. The calculator above can only approximate a segment's impact through the single consolidated growth rate — it cannot model any one line separately. For a true segment-level view, build a separate model from the company's segment disclosures.

Maturity & Competitive Position

Growth / re-investment phase

Moat Signals

Proprietary AI algorithms
Network effect of data accumulation
Integration into clinical workflows

Net income has been negative in the latest period and for 0 out of the last 5 years, indicating a focus on growth over immediate profitability.

Geography & Markets

SOPHiA GENETICS SA is headquartered in Switzerland but operates globally, serving healthcare institutions across Europe, North America, and Asia. Exact geographic revenue splits are not available from current data sources.

Geographic Risks

Regulatory changes in healthcare data privacy and AI
Intense competition in the health tech and genomics space

Market Signals

These are timing signals, not value signals — they describe the stock's recent price behavior, not what the business is worth. Use them for the "the thesis looks good, but is now the moment?" question. Each tile below explains what it's saying.

Model neutral, tape bullish
RSI?RSI — Relative Strength Index — a 0-100 momentum gauge. Above 70 = overbought; below 30 = oversold.
Why it matters: Short-term contrarian indicator. Extreme readings often precede mean reversion, though not always.
Reference: 30–70 normal · >70 overbought · <30 oversold
Full explanation →
(14)
88.2OverboughtBought up hard recently — stretched; pullbacks are common from here.
MACD?MACD — Moving Average Convergence Divergence — compares a fast and a slow price trend to gauge momentum direction.
Why it matters: When the fast line crosses above the slow line, short-term momentum is turning up; below, turning down. A timing cue, not a value signal.
Reference: Line above signal = bullish momentum · below = bearish
Full explanation →
BullishLine above signalThe fast trend is above the slow trend — short-term momentum is currently upward.
50-Day Average$6.50Price above (+21.1%)Price above its 50-day average = near-term uptrend.
200-Day Average$4.93Price aboveThe 200-day line is the long-term trend divider — above it is generally considered a bull market for the stock.
50 vs 200 CrossGolden50-day above 200-dayA "golden cross" — the medium trend has overtaken the long trend (often read as bullish).

Technicals describe price, not the business. A great company can have a "bearish" tape (a buying chance) and a weak one a "bullish" tape (a trap). Pair these with the valuation and health sections above.

Data Quality & Risk Flags (4 notes — click to expand/collapse)

Guardrail Notes (4)
  • FCF negative: revenue/margin growth model projects future cash flows from revenue trajectory.
  • INVARIANT: weighted IV is non-positive. Model may not be appropriate.
  • Model implies no positive equity value under these assumptions. Valuation is speculative/low-confidence.
  • Illiquidity discount 7% applied (small/micro-cap — harder to exit, demand a margin).

Financial Statements (5-year tables — click to expand)

From SOPHiA GENETICS SA's SEC filings (EDGAR).

Income (5yr)

YearRevenueNet IncomeEPS
2025-79.0M$-1.15
2024-62.5M$-0.91
2023-79.0M$-1.15
2022-87.4M$-1.28
2021-73.7M$-1.08

Balance Sheet

Total Assets163.0M
Total Liabilities115.9M
Equity

Similar companies worth a look

Same sector and industry, similar fundamentals shape. Verify everything yourself — this list is computed mechanically and does not reflect our judgment about whether any of these are a good investment.

PG
Methodology by Pouyan Golshani, MD — founder of Gighz. Savng was built by a physician for busy professionals: every number on this page comes from SEC filings (EDGAR) and FINRA data through transparent, rules-based models — no analyst opinions, no hidden inputs. How we calculate every number →
⚠️ Not investment advice. Automated model outputs, last refreshed May 30, 2026 (the analysis-refresh date, not the latest filing period). All models have blind spots. Full disclaimer →
🔔 Follow $SOPH — free insider alerts
One email when an insider buys $SOPH on the open market with their own cash — or notably sells outside a scheduled plan. Routine and automated trades filtered out. Follow up to 3 stocks free; Portfolio Watch covers your whole list plus valuation & risk alerts. Double opt-in, unsubscribe anytime.